|
1.
|
de Lange T: Shelterin: the protein complex
that shapes and safeguards human telomeres. Genes Dev.
19:2100–2110. 2005.PubMed/NCBI
|
|
2.
|
Palm W and de Lange T: How shelterin
protects mammalian telomeres. Annu Rev Genet. 42:301–334. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Morin GB: The human telomere terminal
transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG
repeats. Cell. 59:521–529. 1989. View Article : Google Scholar
|
|
4.
|
Cohen SB, Graham ME, Lovrecz GO, Bache N,
Robinson PJ and Reddel RR: Protein composition of catalytically
active human telomerase from immortal cells. Science.
315:1850–1853. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Blackburn EH: Switching and signaling at
the telomere. Cell. 106:661–673. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Pinto AR, Li H, Nicholls C and Liu JP:
Telomere protein complexes and interactions with telomerase in
telomere maintenance. Front Biosci. 16:187–207. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Agrelo R and Wutz A: Cancer progenitors
and epigenetic contexts: an Xisting connection. Epigenetics.
4:568–570. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Vineis P, Chuang SC, Vaissière T, Cuenin
C, Ricceri F; Genair-EPIC Collaborators; Johansson M, Ueland P,
Brennan P and Herceg Z: DNA methylation changes associated with
cancer risk factors and blood levels of vitamin metabolites in a
prospective study. Epigenetics. 6:195–201. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Laird PW: The power and the promise of DNA
methylation markers. Nat Rev Cancer. 3:253–266. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Baylin SB and Ohm JE: Epigenetic gene
silencing in cancer - a mechanism for early oncogenic pathway
addiction? Nat Rev Cancer. 6:107–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Shao C, Lacey M, Dubeau L and Ehrlich M:
Hemimethylation footprints of DNA demethylation in cancer.
Epigenetics. 4:165–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Sawan C and Herceg Z: Histone
modifications and cancer. Adv Genet. 70:57–85. 2010. View Article : Google Scholar
|
|
14.
|
Rivière G, Lienhard D, Andrieu T, Vieau D,
Frey BM and Frey FJ: Epigenetic regulation of somatic
angiotensin-converting enzyme by DNA methylation and histone
acetylation. Epigenetics. 6:478–489. 2011.PubMed/NCBI
|
|
15.
|
Cairney CJ and Keith WN: Telomerase
redefined: integrated regulation of hTR and hTERT for telomere
maintenance and telomerase activity. Biochimie. 90:13–23. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Dessain SK, Yu H, Reddel RR, Beijersbergen
RL and Weinberg RA: Methylation of the human telomerase gene CpG
island. Cancer Res. 60:537–541. 2000.PubMed/NCBI
|
|
17.
|
Zhu J, Zhao Y and Wang S: Chromatin and
epigenetic regulation of the telomerase reverse transcriptase gene.
Protein Cell. 1:22–32. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Iliopoulos D, Oikonomou P, Messinis I and
Tsezou A: Correlation of promoter hypermethylation in hTERT, DAPK
and MGMT genes with cervical oncogenesis progression. Oncol Rep.
22:199–204. 2009.PubMed/NCBI
|
|
19.
|
Gigek CO, Leal MF, Silva PN, Lisboa LC,
Lima EM, Calcagno DQ, Assumpção PP, Burbano RR and Smith Mde A:
hTERT methylation and expression in gastric cancer. Biomarkers.
14:630–636. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Wang S, Hu C and Zhu J: Distinct and
temporal roles of nucleosomal remodeling and histone deacetylation
in the repression of the hTERT gene. Mol Biol Cell. 21:821–832.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Jia W, Wang S, Horner JW, Wang N, Wang H,
Gunther EJ, DePinho RA and Zhu J: A BAC transgenic reporter
recapitulates in vivo regulation of human telomerase reverse
transcriptase in development and tumorigenesis. FASEB J.
25:979–989. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Baird DM, Rowson J, Wynford-Thomas D and
Kipling D: Extensive allelic variation and ultrashort telomeres in
senescent human cells. Nat Genet. 33:203–207. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Harley CB, Futcher AB and Greider CW:
Telomeres shorten during ageing of human fibroblasts. Nature.
345:458–460. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Li Y, Liu L, Andrews LG and Tollefsbol TO:
Genistein depletes telomerase activity through cross-talk between
genetic and epigenetic mechanisms. Int J Cancer. 125:286–296. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Egger G, Liang G, Aparicio A and Jones PA:
Epigenetics in human disease and prospects for epigenetic therapy.
Nature. 429:457–463. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Lopatina NG, Poole JC, Saldanha SN, Hansen
NJ, Key JS, Pita MA, Andrews LG and Tollefsbol TO: Control
mechanisms in the regulation of telomerase reverse transcriptase
expression in differentiating human teratocarcinoma cells. Biochem
Biophys Res Commun. 306:650–659. 2003. View Article : Google Scholar
|
|
27.
|
Shin KH, Kang MK, Dicterow E and Park NH:
Hypermethylation of the hTERT promoter inhibits the expression of
telomerase activity in normal oral fibroblasts and senescent normal
oral keratinocytes. Br J Cancer. 89:1473–1478. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Zinn RL, Pruitt K, Eguchi S, Baylin SB and
Herman JG: hTERT is expressed in cancer cell lines despite promoter
DNA methylation by preservation of unmethylated DNA and active
chromatin around the transcription start site. Cancer Res.
67:194–201. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Devereux TR, Horikawa I, Anna CH, Annab
LA, Afshari CA and Barrett JC: DNA methylation analysis of the
promoter region of the human telomerase reverse transcriptase
(hTERT) gene. Cancer Res. 59:6087–6090. 1999.PubMed/NCBI
|
|
30.
|
Kumari A, Srinivasan R, Vasishta RK and
Wig JD: Positive regulation of human telomerase reverse
transcriptase gene expression and telomerase activity by DNA
methylation in pancreatic cancer. Ann Surg Oncol. 16:1051–1059.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Kumari A, Srinivasan R and Wig JD: Effect
of c-MYC and E2F1 gene silencing and of 5-azacytidine treatment on
telomerase activity in pancreatic cancer-derived cell lines.
Pancreatology. 9:360–368. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Guilleret I, Yan P, Grange F, Braunschweig
R, Bosman FT and Benhattar J: Hypermethylation of the human
telomerase catalytic subunit (hTERT) gene correlates with
telomerase activity. Int J Cancer. 101:335–341. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Krajewski WA: Histone acetylation status
and DNA sequence modulate ATP-dependent nucleosome repositioning. J
Biol Chem. 277:14509–14513. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Lai SR, Phipps SM, Liu L, Andrews LG and
Tollefsbol TO: Epigenetic control of telomerase and modes of
telomere maintenance in aging and abnormal systems. Front Biosci.
10:1779–1796. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Takakura M, Kyo S, Sowa Y, Wang Z, Yatabe
N, Maida Y, Tanaka M and Inoue M: Telomerase activation by histone
deacetylase inhibitor in normal cells. Nucleic Acids Res.
29:3006–3011. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Hou M, Wang X, Popov N, Zhang A, Zhao X,
Zhou R, Zetterberg A, Björkholm M, Henriksson M, Gruber A and Xu D:
The histone deacetylase inhibitor trichostatin A derepresses the
telomerase reverse transcriptase (hTERT) gene in human cells. Exp
Cell Res. 274:25–34. 2002. View Article : Google Scholar
|
|
37.
|
Murakami J, Asaumi J, Kawai N, Tsujigiwa
H, Yanagi Y, Nagatsuka H, Inoue T, Kokeguchi S, Kawasaki S, Kuroda
M, Tanaka N, Matsubara N and Kishi K: Effects of histone
deacetylase inhibitor FR901228 on the expression level of
telomerase reverse transcriptase in oral cancer. Cancer Chemother
Pharmacol. 56:22–28. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Zhu K, Qu D, Sakamoto T, Fukasawa I,
Hayashi M and Inaba N: Telomerase expression and cell proliferation
in ovarian cancer cells induced by histone deacetylase inhibitors.
Arch Gynecol Obstet. 277:15–19. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Suenaga M, Soda H, Oka M, Yamaguchi A,
Nakatomi K, Shiozawa K, Kawabata S, Kasai T, Yamada Y, Kamihira S,
Tei C and Kohno S: Histone deacetylase inhibitors suppress
telomerase reverse transcriptase mRNA expression in prostate cancer
cells. Int J Cancer. 97:621–625. 2002. View Article : Google Scholar
|
|
40.
|
Khaw AK, Silasudjana M, Banerjee B, Suzuki
M, Baskar R and Hande MP: Inhibition of telomerase activity and
human telomerase reverse transcriptase gene expression by histone
deacetylase inhibitor in human brain cancer cells. Mutat Res.
625:134–144. 2007. View Article : Google Scholar
|
|
41.
|
Rice JC, Briggs SD, Ueberheide B, Barber
CM, Shabanowitz J, Hunt DF, Shinkai Y and Allis CD: Histone
methyltransferases direct different degrees of methylation to
define distinct chromatin domains. Mol Cell. 12:1591–1598. 2003.
View Article : Google Scholar
|
|
42.
|
Atkinson SP, Hoare SF, Glasspool RM and
Keith WN: Lack of telomerase gene expression in alternative
lengthening of telomere cells is associated with chromatin
remodeling of the hTR and hTERT gene promoters. Cancer Res.
65:7585–7590. 2005.PubMed/NCBI
|
|
43.
|
Liu C, Fang X, Ge Z, Jalink M, Kyo S,
Björkholm M, Gruber A, Sjöberg J and Xu D: The telomerase reverse
transcriptase (hTERT) gene is a direct target of the histone
methyltransferase SMYD3. Cancer Res. 67:2626–26. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
44.
|
Röth A, Vercauteren S, Sutherland HJ and
Lansdorp PM: Telomerase is limiting the growth of acute myeloid
leukemia cells. Leukemia. 17:2410–2417. 2003.PubMed/NCBI
|
|
45.
|
Annaloro C, Onida F, Saporiti G and
Lambertenghi Deliliers G: Cancer stem cells in hematological
disorders: current and possible new therapeutic approaches. Curr
Pharm Biotechnol. 12:217–225. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46.
|
Liu L, Saldanha SN, Pate MS, Andrews LG
and Tollefsbol TO: Epigenetic regulation of human telomerase
reverse transcriptase promoter activity during cellular
differentiation. Genes Chromosomes Cancer. 41:26–37. 2004.
View Article : Google Scholar
|
|
47.
|
Bechter OE, Eisterer W, Dlaska M, Kühr T
and Thaler J: CpG island methylation of the hTERT promoter is
associated with lower telomerase activity in B-cell lymphocytic
leukemia. Exp Hematol. 30:26–33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48.
|
Terrin L, Trentin L, Degan M, Corradini I,
Bertorelle R, Carli P, Maschio N, Bo MD, Noventa F, Gattei V,
Semenzato G and De Rossi A: Telomerase expression in B-cell chronic
lymphocytic leukemia predicts survival and delineates subgroups of
patients with the same igVH mutation status and different outcome.
Leukemia. 21:965–972. 2007.
|
|
49.
|
Lübbert M, Suciu S, Baila L, Rüter BH,
Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U,
Salih HR, Beeldens F, Muus P, Pflüger KH, Coens C, Hagemeijer A,
Eckart Schaefer H, Ganser A, Aul C, de Witte T and Wijermans PW:
Low-dose decitabine versus best supportive care in elderly patients
with intermediate- or high-risk myelodysplastic syndrome (MDS)
ineligible for intensive chemotherapy: final results of the
randomized phase III study of the European Organisation for
Research and Treatment of Cancer Leukemia Group and the German MDS
Study Group. J Clin Oncol. 29:1987–1996. 2011.
|
|
50.
|
Kantarjian HM, Giles FJ, Greenberg PL,
Paquette RL, Wang ES, Gabrilove JL, Garcia-Manero G, Hu K, Franklin
JL and Berger DP: Phase 2 study of romiplostim in patients with
low- or intermediate-risk myelodysplastic syndrome receiving
azacitidine therapy. Blood. 116:3163–3170. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51.
|
Baer MR and Gojo I: Novel agents for the
treatment of acute myeloid leukemia in the older patient. J Natl
Compr Canc Netw. 9:331–335. 2011.
|
|
52.
|
Garcia-Manero G, Gore SD, Cogle C, Ward R,
Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E,
Kantarjian H and Skikne B: Phase I study of oral azacitidine in
myelodysplastic syndromes, chronic myelomonocytic leukemia, and
acute myeloid leukemia. J Clin Oncol. 29:2521–2527. 2011.
View Article : Google Scholar
|
|
53.
|
Claus R and Lübbert M: Epigenetic targets
in hematopoietic malignancies. Oncogene. 22:6489–6496. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
54.
|
Lane AA and Chabner BA: Histone
deacetylase inhibitors in cancer therapy. J Clin Oncol.
27:5459–5468. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55.
|
Pendino F, Sahraoui T, Lanotte M and
Ségal-Bendirdjian E: A novel mechanism of retinoic acid resistance
in acute promyelocytic leukemia cells through a defective pathway
in telomerase regulation. Leukemia. 16:826–832. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
56.
|
Pendino F, Flexor M, Delhommeau F, Buet D,
Lanotte M and Segal-Bendirdjian E: Retinoids down-regulate
telomerase and telomere length in a pathway distinct from leukemia
cell differentiation. Proc Natl Acad Sci USA. 98:6662–6667. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
57.
|
Kretzner L, Scuto A, Dino PM, Kowolik CM,
Wu J, Ventura P, Jove R, Forman SJ, Yen Y and Kirschbaum MH:
Combining histone deacetylase inhibitor vorinostat with aurora
kinase inhibitors enhances lymphoma cell killing with repression of
c-Myc, hTERT, and microRNA levels. Cancer Res. 71:3912–3920. 2011.
View Article : Google Scholar
|
|
58.
|
Quintás-Cardama A, Santos FP and
Garcia-Manero G: Histone deacetylase inhibitors for the treatment
of myelodysplastic syndrome and acute myeloid leukemia. Leukemia.
25:226–235. 2011.PubMed/NCBI
|
|
59.
|
Azouz A, Wu YL, Hillion J, Tarkanyi I,
Karniguian A, Aradi J, Lanotte M, Chen GQ, Chehna M and
Ségal-Bendirdjian E: Epigenetic plasticity of hTERT gene promoter
determines retinoid capacity to repress telomerase in
maturation-resistant acute promyelocytic leukemia cells. Leukemia.
24:613–622. 2010. View Article : Google Scholar
|
|
60.
|
Love WK, Berletch JB, Andrews LG and
Tollefsbol TO: Epigenetic regulation of telomerase in
retinoid-induced differentiation of human leukemia cells. Int J
Oncol. 32:625–631. 2008.PubMed/NCBI
|
|
61.
|
Woo HJ, Lee SJ, Choi BT, Park YM and Choi
YH: Induction of apoptosis and inhibition of telomerase activity by
trichostatin A, a histone deacetylase inhibitor, in human leukemic
U937 cells. Exp Mol Pathol. 82:77–84. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
62.
|
Okabe S, Tauchi T, Nakajima A, Sashida G,
Gotoh A, Broxmeyer HE, Ohyashiki JH and Ohyashiki K: Depsipeptide
(FK228) preferentially induces apoptosis in BCR/ABL-expressing cell
lines and cells from patients with chronic myelogenous leukemia in
blast crisis. Stem Cells Dev. 16:503–514. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
63.
|
Deville L, Hillion J, Pendino F, Samy M,
Nguyen E and Ségal-Bendirdjian E: hTERT promotes imatinib
resistance in chronic myeloid leukemia cells: therapeutic
implications. Mol Cancer Ther. 10:711–719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
64.
|
Nakajima A, Tauchi T, Sashida G, Sumi M,
Abe K, Yamamoto K, Ohyashiki JH and Ohyashiki K: Telomerase
inhibition enhances apoptosis in human acute leukemia cells:
possibility of anti-telomerase therapy. Leukemia. 17:560–567. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
65.
|
Tauchi T, Shin-ya K, Sashida G, Sumi M,
Okabe S, Ohyashiki JH and Ohyashiki K: Telomerase inhibition with a
novel G-quadruplex-interactive agent, telomestatin: in vitro and in
vivo studies in acute leukemia. Oncogene. 25:5719–5725. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
66.
|
Altucci L, Clarke N, Nebbioso A,
Scognamiglio A and Gronemeyer H: Acute myeloid leukemia:
therapeutic impact of epigenetic drugs. Int J Biochem Cell Biol.
37:1752–1762. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
67.
|
Bhalla KN: Epigenetic and chromatin
modifiers as targeted therapy of hematologic malignancies. J Clin
Oncol. 23:3971–3993. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
68.
|
Piekarz RL and Bates SE: Epigenetic
modifiers: basic understanding and clinical development. Clin
Cancer Res. 15:3918–3926. 2009. View Article : Google Scholar : PubMed/NCBI
|
